Outcomes of Systemic Janus Kinase Inhibitors Following Dupilumab for Dupilumab-Associated Facial and Neck Erythema: A Systematic Review

Dupilumab, an anti-IL-13 and anti-IL-4 antibody, is a mainstay of treatment for moderate-to-severe atopic dermatitis. However, dupilumab-associated facial and/or neck erythema (DA-FNE) has been reported to be a relatively common adverse event. There have been increasing reports of systemic Janus Kinase Inhibitors (JAKi) as a potential treatment for DA-FNE. Here we systematically review the outcomes of patients who initiated JAKi after discontinuation from dupilumab for DA-FNE.